Continuous glucose monitoring (CGM)

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in June 2024. Twelve recommendations were published concerning the registration of medical devices or modification of registration conditions/extension of indications for the medical devices in the List of Reimbursable Products and Services (LPPR). Opinions concern cardiovascular and endocrine devices, as well as medical aids.

In March 2024, several method assessments were initiated as a part of a framework for the managed introduction of innovations "New Methods" for cardiovascular, endocrine, gastrointestinal, men’s health, neurology and neurosurgery, neuromodulation, obstetrics and gynecology, robotic surgery, and some other fields.

In March 2024, the Evaluation and Planning Service of the Canary Islands Health Service (SESCS) is working on several HTAs, including evaluations in the cardiovascular, endocrine, neurology and neurosurgery, orthopedics, surgical procedures, and some other fields.

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in February 2024. Fourteen recommendations were published concerning the registration of medical devices or modification of registration conditions with the extension of indications for the medical devices in the List of Reimbursable Products and Services (LPPR). Opinions concern cardiovascular, neurovascular, neuromodulation, endocrine, and endoscopy devices, as well as medical aids.

On January 22, 2024, NHS England published a 5-year implementation strategy for Hybrid closed loop (HCL) technologies following the NICE technology appraisal (TA943) publication. As a rule, commissioners and providers must implement TA recommendations within three months. However, an agreed five-year implementation will allow NHS to build specialist competencies and cost-effective procurement. NHS England will fund integrated care boards to reimburse the use of HCL systems

In December 2023, the National Institute for Health and Care Excellence (NICE) published one new Interventional Procedure Guidance (middle meningeal artery embolization for chronic subdural hematomas), one Technology Appraisal Guidance (Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes, and one new clinical guideline.

Continuous glucose monitoring (rtCGM) and flash glucose monitoring (FGM) for adults with type 1 diabetes have been evaluated within the "New Methods" framework since June 2023. In November 2023, a simplified method assessment report was published. On December 11, 2023, the Decision Forum for "New Methods" recommended introducing rtCGM and FGM.

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in October 2023. Twelve recommendations were published in relation to the registration of medical devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular, e-health, endocrine, gastrointestinal, neurology and neurosurgery, neuromodulation, and orthopedic devices, as well as medical aids.

In August 2023, the Evaluation and Planning Service of the Canary Islands Health Service (SESCS) is working on several HTAs, including evaluations in the cardiovascular, endocrine, neurology and neurosurgery, orthopedics, surgical procedures, and some other fields.

On July 1, 2023, the National Institute for Health and Disability Insurance (INAMI-RIZIV) updated the conditions of reimbursement for continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM, commonly called flash glucose monitoring, FGM). Full coverage by health insurance became available to more patient categories.

In May 2023, the National Institute for Health and Care Excellence (NICE) published one new Interventional Procedure Guidance (intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries), two new Diagnostic Guidance (MRI fusion biopsy systems for diagnosing prostate cancer, automated ankle-brachial pressure index measurement devices to detect peripheral arterial disease), and three new Health Technology Evaluations (Digitally enabled therapies for adults with anxiety disorders / with depression, and point-of-care tests for urinary tract infections). Also, four clinical guidelines were updated.

In March 2023, the Danish Health Technology Council (Behandlingsrådet) completed a major analysis (større analyser) on patient-centered diabetes technology. The Council recommended that sensor-based glucose monitoring devices with alarms be offered to all adult patients with type 1 diabetes.